166 related articles for article (PubMed ID: 10348772)
1. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses.
Auclair B; Ducharme MP
Antimicrob Agents Chemother; 1999 Jun; 43(6):1465-8. PubMed ID: 10348772
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment.
Derendorf H; Dalla Costa T
Int J Clin Pharmacol Ther; 1996 Nov; 34(11):482-8. PubMed ID: 8937930
[TBL] [Abstract][Full Text] [Related]
5. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister PD; Prevan AM; Sanders CC
Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants.
Li Z; Chen Y; Li Q; Cao D; Shi W; Cao Y; Wu D; Zhu Y; Wang Y; Chen C
Eur J Clin Pharmacol; 2013 Jun; 69(6):1223-33. PubMed ID: 23354809
[TBL] [Abstract][Full Text] [Related]
7. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.
Cohen-Wolkowiez M; Watt KM; Zhou C; Bloom BT; Poindexter B; Castro L; Gao J; Capparelli EV; Benjamin DK; Smith PB
Antimicrob Agents Chemother; 2014 May; 58(5):2856-65. PubMed ID: 24614369
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
9. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
Sörgel F; Kinzig M
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():39-60. PubMed ID: 8383655
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Sörgel F; Kinzig M
Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
[TBL] [Abstract][Full Text] [Related]
11. Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis.
Dalla Costa T; Nolting A; Kovar A; Derendorf H
J Antimicrob Chemother; 1998 Dec; 42(6):769-78. PubMed ID: 10052901
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
14. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.
Mueller SC; Majcher-Peszynska J; Hickstein H; Francke A; Pertschy A; Schulz M; Mundkowski R; Drewelow B
Antimicrob Agents Chemother; 2002 May; 46(5):1557-60. PubMed ID: 11959598
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Mattoes HM; Capitano B; Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2002 May; 48(2):59-63. PubMed ID: 12011536
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
19. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
Valtonen M; Tiula E; Takkunen O; Backman JT; Neuvonen PJ
J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
